Topics
Glioblastoma | Treatment | Clinical trials | Margins
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Margins
Tang PLY, Romero AM, Nout RA, van Rij C, Slagter C, Swaak-Kragten
AT, Smits M, Warnert EAH.
Amide proton
transfer-weighted CEST MRI for radiotherapy target delineation of
glioblastoma: a prospective pilot study.
Eur
Radiol Exp. 2024 Oct 30;8(1):123. doi:
10.1186/s41747-024-00523-4. PMID:
39477835. Interventional study. ˍ
Grosu AL, Weber WA, Graf E, Mix M, Nestle U, Schimek-Jasch T,
Wiehle R, Mader I, Würtemberger U, Langen KJ, Niyazi M,
Paulsen F, König L, Giordano FA, Spehl I, Bernhardt D,
Schymalla MM, Pöttgen C, Semrau S, Brunner T, Hültenschmidt
B, Krause BJ, Ciernik IF, Beck J, Baumert BG, Meyer PT, Urbach H,
Popp I; GLIAA Study Group.
O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided
versus contrast-enhanced T1-weighted MRI-guided re-irradiation in
patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a
multicentre, open-label, randomised trial.
Lancet
Oncol. 2025 Dec 19:S1470-2045(25)00642-4. doi:
10.1016/S1470-2045(25)00642-4. PMID:
41429128. Interventional study. ˍ